Logo image of APPH.DE

APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis

FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR

10.8  0 (0%)

Fundamental Rating

4

Overall APPH gets a fundamental rating of 4 out of 10. We evaluated APPH against 50 industry peers in the Pharmaceuticals industry. While APPH has a great health rating, there are worries on its profitability. While showing a medium growth rate, APPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APPH was profitable.
In the past year APPH has reported a negative cash flow from operations.
In multiple years APPH reported negative net income over the last 5 years.
In multiple years APPH reported negative operating cash flow during the last 5 years.
APPH.DE Yearly Net Income VS EBIT VS OCF VS FCFAPPH.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

With a Return On Assets value of 2.82%, APPH is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
APPH has a Return On Equity of 4.03%. This is in the lower half of the industry: APPH underperforms 60.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.95%, APPH is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA 2.82%
ROE 4.03%
ROIC 2.95%
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
APPH.DE Yearly ROA, ROE, ROICAPPH.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin of APPH (1.75%) is worse than 60.00% of its industry peers.
Looking at the Operating Margin, with a value of 2.47%, APPH is doing worse than 64.00% of the companies in the same industry.
In the last couple of years the Operating Margin of APPH has declined.
Looking at the Gross Margin, with a value of 57.57%, APPH is doing worse than 66.00% of the companies in the same industry.
In the last couple of years the Gross Margin of APPH has declined.
Industry RankSector Rank
OM 2.47%
PM (TTM) 1.75%
GM 57.57%
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
APPH.DE Yearly Profit, Operating, Gross MarginsAPPH.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APPH is destroying value.
Compared to 1 year ago, APPH has about the same amount of shares outstanding.
APPH has less shares outstanding than it did 5 years ago.
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APPH.DE Yearly Shares OutstandingAPPH.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
APPH.DE Yearly Total Debt VS Total AssetsAPPH.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 5.97 indicates that APPH is not in any danger for bankruptcy at the moment.
APPH's Altman-Z score of 5.97 is amongst the best of the industry. APPH outperforms 88.00% of its industry peers.
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.97
ROIC/WACC0.42
WACC7.07%
APPH.DE Yearly LT Debt VS Equity VS FCFAPPH.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 4.44 indicates that APPH has no problem at all paying its short term obligations.
The Current ratio of APPH (4.44) is better than 100.00% of its industry peers.
APPH has a Quick Ratio of 3.37. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.37, APPH belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 3.37
APPH.DE Yearly Current Assets VS Current LiabilitesAPPH.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 106.67% over the past year.
The Revenue has grown by 31.12% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.89% on average over the past years.
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%

3.2 Future

The Earnings Per Share is expected to grow by 128.83% on average over the next years. This is a very strong growth
APPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.31% yearly.
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year15.94%
Revenue Next 2Y18.51%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APPH.DE Yearly Revenue VS EstimatesAPPH.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
APPH.DE Yearly EPS VS EstimatesAPPH.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 72.00, APPH can be considered very expensive at the moment.
APPH's Price/Earnings ratio is a bit more expensive when compared to the industry. APPH is more expensive than 68.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.50, APPH is valued quite expensively.
A Price/Forward Earnings ratio of 24.40 indicates a rather expensive valuation of APPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of APPH indicates a slightly more expensive valuation: APPH is more expensive than 60.00% of the companies listed in the same industry.
APPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 72
Fwd PE 24.4
APPH.DE Price Earnings VS Forward Price EarningsAPPH.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

62.00% of the companies in the same industry are cheaper than APPH, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.05
APPH.DE Per share dataAPPH.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APPH's earnings are expected to grow with 128.83% in the coming years.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y175.34%
EPS Next 3Y128.83%

More info and screens

0

5. Dividend

5.1 Amount

APPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APONTIS PHARMA AG

FRA:APPH (7/17/2025, 7:00:00 PM)

10.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)N/A N/A
Inst Owners40.82%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap91.80M
Analysts42
Price Target13.77 (27.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-5.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE 72
Fwd PE 24.4
P/S 1.28
P/FCF N/A
P/OCF N/A
P/B 2.96
P/tB 6.87
EV/EBITDA 19.05
EPS(TTM)0.15
EY1.39%
EPS(NY)0.44
Fwd EY4.1%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS8.43
BVpS3.65
TBVpS1.57
PEG (NY)0.25
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.82%
ROE 4.03%
ROCE 4.51%
ROIC 2.95%
ROICexc 4.86%
ROICexgc 18.85%
OM 2.47%
PM (TTM) 1.75%
GM 57.57%
FCFM N/A
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-34.78%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.05%
ROICexc growth 5YN/A
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 104.52%
Cap/Sales 3.27%
Interest Coverage 13.13
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 3.37
Altman-Z 5.97
F-Score5
WACC7.07%
ROIC/WACC0.42
Cap/Depr(3y)153.41%
Cap/Depr(5y)119.86%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
Revenue Next Year15.94%
Revenue Next 2Y18.51%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
EBIT growth 1Y113.23%
EBIT growth 3Y-33.96%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y66.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.97%
OCF growth 3YN/A
OCF growth 5YN/A